While anti-VEGF agents have demonstrated efficacy in the treatment of renal cell, hepatocellular, colorectal, non-small cell lung, and ovarian cancers, such agents have shown only modest effects on long-term prognosis in breast, pancreatic, and prostate cancers [14]. The gene discussed is VEGFA; the disease is prostate cancer.